How to Source Givinostat for Pharmaceutical Formulation
Givinostat (Oral suspension, 8.86 mg/mL) is classified under Neurology. It is therapeutically aligned with reference brands such as Duvyzat (USA/EU). This guide highlights key sourcing factors buyers should consider when procuring high-quality Givinostat for formulation, R&D, or bulk manufacturing.
Product Overview:
Givinostat is a histone deacetylase (HDAC) inhibitor which works by inhibiting class I and II HDAC enzymes, reducing inflammation, muscle degeneration and fibrosis in patients with Duchenne muscular dystrophy. It is indicated for patients aged 6 years and older with DMD, regardless of specific genetic variant.
The medication is given as a twice daily oral suspension with food, and requires monitoring of blood counts and triglycerides due to risks of thrombocytopenia and hypertriglyceridaemia.
Givinostat API – ideal for compliant pharmaceutical formulation.
Quick Insight: Over 60% of formulation delays are linked to poor API sourcing. A well-planned sourcing strategy can reduce risk and accelerate market entry.
1. Regulatory Compliance & Documentation
Ensure suppliers provide:
- ✔ Valid DMF (Drug Master File)
- ✔ COA (Certificate of Analysis) for each batch
- ✔ GMP, ISO, or ICH Q7 compliance certificates
2. Purity, Grade & Specification Matching
Givinostat must meet exact grade and purity for your dosage form:
- ✔ USP / EP / JP grade verification
- ✔ Particle size distribution check
- ✔ Residual solvent and heavy metal limits
3. Supplier Reliability & Audit History
- ✔ Positive past audit reports
- ✔ Pharma client references
- ✔ Years of proven API manufacturing experience
4. Commercial Terms: Pricing, MOQ & Flexibility
- ✔ Transparent pricing
- ✔ Pilot batch MOQ flexibility
- ✔ Volume-based discounts
5. Lead Time, Inventory & Logistics
Typical lead time for Givinostat is 4–6 weeks.
- ✔ Emergency dispatch options
- ✔ Regional warehousing
- ✔ Special storage if needed
6. Formulation Support
- ✔ Technical datasheets
- ✔ Sample availability
- ✔ Stability study support
Pro Tip: Engage supplier formulation experts early — it can improve bioavailability and cut development time.
Conclusion
Sourcing Givinostat is more than procurement—it’s a strategic partnership. With its oral suspension form and 8.86 mg/mL specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.
Frequently Asked Questions For Sourcing of Givinostat
What is the typical lead time for Givinostat?
Lead times range from 4–6 weeks depending on supplier and region.
Is Givinostat available in multiple grades?
Yes — common grades include USP, EP, and JP. Verify grade suitability for your dosage form before purchase.
Does Givinostat require special storage?
It should be stored in a cool, dry place away from direct sunlight.
Is a Drug Master File (DMF) available for Givinostat?
Yes, a DMF is available for regulated markets upon request. It includes detailed quality, manufacturing, and stability data.
Can I request samples or a pilot batch of Givinostat?
Yes — pilot batches or samples can be arranged for R&D, stability studies, or formulation trials. MOQ may vary based on region and regulatory scope.
What compliance certificates are available for Givinostat?
Available documentation may include GMP, ISO 9001, ISO 14001, and ICH Q7 certificates, along with CoA, TDS, and stability data.
Is Givinostat suitable for regulated markets like US/EU?
Yes — compliant with EU/US/WHO GMP standards and available with regulatory support documentation for filings.
Can Givinostat be used in fixed-dose combinations?
Yes — many formulations support inclusion in FDCs. Compatibility studies and formulation consultation are available on request.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our
Privacy Policy.